Taysha Gene Therapies completed patient dosing in two of its key Rett syndrome trials, marking critical progress toward a potential new gene therapy. With second quarter 2026 financial results reinforcing its commitment, the company aims to share top-line data and pursue FDA milestones in the year ahead.